...A. There's the 2019 acquisitions of (inaudible) stake of Verge Surgical, a lot of internal efforts you guys have been delivering the (inaudible) soft tissue (inaudible) program. B. One is the lung broncoscopy, more than 35,000 cases in the U.S. We're the first to get approval in China, and we're excited to bring that technology to China because, as you know, lung cancer in China is 40% of all lung cancer cases globally. C. It's 5% global penetration. D. I think that was Orthotaxy acquisition that drove the development there. E. Thinking about the $10 billion Ethicon business unit, I mean, how should ultimately investors think about the revenue growth contributions from these robotic efforts. F. We look at our performance, we were growing at 1.5% in 2017. G. You fast forward to end of last year, we grew at (inaudible) % without Abimed. H. That's an incredible performance because we're a $30 billion company and to be able to have that sequential improvement is incredible, but it happened...
